Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma

Inclusion Criteria: * Men or women ≥ 60 years old with estimated life expectancy of ≥ 5 years * Histopathologic diagnosis of basal or squamous cell carcinoma * Clinical stage T1N0M0 (by AJCC 2010 criteria) °Basal cell carcinoma with morpheaform, sclerosing, mixed, infiltrative or micronodular features must be ≤1 cm * Low risk pathologic features (by AJCC 2010 criteria) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-3 (Appendix C) * Able and willing to complete the Skindex16 and Skin Cancer Index (must be able to speak English) * Ability to provide informed consent Exclusion Criteria: * BCC/SCC that was previously treated (ie, recurrent BCC/SCC) * BCC/SCC in region adjacent to or overlapping with region of prior radiotherapy * BCC/SCC on irregular surface (ie, target area not flat) * BCC/SCC adjacent to or overlapping with burn or scar * BCC/SCC in area prone to trauma (including, but not limited to the skin overlying the tibia, dorsum of hands and elbow) * BCC/SCC in area with compromised lymphatic drainage or vascular supply * BCC/SCC within 3 cm of another treated or untreated BCC/SCC * Inflammatory process in target area * Collagen vascular disease (lupus, scleroderma, rheumatoid arthritis) * Diabetes that is poorly controlled * Genetic disorder predisposing patient to skin cancers or radiation sensitivity (basal cell nevus syndrome, xeroderma pigmentosum, ataxia telangiectasia mutans) * Receipt of treatment with another investigational device or drug * Receipt of drug that will affect biologic response to radiation (radiosensitizer or radioprotector) * High likelihood of protocol non-compliance (in opinion of investigator)